4/24
03:31 pm
akro
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
4/22
08:03 am
akro
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at Bank of America Co.. They set a "neutral" rating and a $30.00 price target on the stock.
Low
Report
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at Bank of America Co.. They set a "neutral" rating and a $30.00 price target on the stock.
4/20
12:15 pm
akro
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
4/18
03:15 pm
akro
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
4/17
11:00 am
akro
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Low
Report
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
4/16
02:54 pm
akro
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO
4/16
11:00 am
akro
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Low
Report
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
4/15
11:00 am
akro
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Low
Report
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
11/13/2023
07:00 am
akro
akero therapeutics, inc.
MISS
Report
2.2%
akero therapeutics, inc.
8/11/2023
06:00 am
akro
akero therapeutics, inc.
BEAT
Report
4.5%
akero therapeutics, inc.
5/15/2023
07:00 am
akro
akero therapeutics, inc.
BEAT
Report
3.0%
akero therapeutics, inc.
4/16
04:31 pm
akro
Form PRE 14A Akero Therapeutics, Inc. For: Jun 07
Low
Report
Form PRE 14A Akero Therapeutics, Inc. For: Jun 07
4/3
06:56 pm
akro
Form 4 Akero Therapeutics, Inc. For: Apr 01 Filed by: Young Jonathan
Medium
Report
Form 4 Akero Therapeutics, Inc. For: Apr 01 Filed by: Young Jonathan
4/1
04:18 pm
akro
Form 144 Akero Therapeutics, Inc. Filed by: Young Jonathan
Low
Report
Form 144 Akero Therapeutics, Inc. Filed by: Young Jonathan
3/18
04:31 pm
akro
Form 8-K Akero Therapeutics, Inc. For: Mar 12
Medium
Report
Form 8-K Akero Therapeutics, Inc. For: Mar 12
3/15
04:48 pm
akro
Form 4 Akero Therapeutics, Inc. For: Mar 13 Filed by: Yale Catriona
Medium
Report
Form 4 Akero Therapeutics, Inc. For: Mar 13 Filed by: Yale Catriona
3/15
04:47 pm
akro
Form 4 Akero Therapeutics, Inc. For: Mar 13 Filed by: Cheng Andrew
Medium
Report
Form 4 Akero Therapeutics, Inc. For: Mar 13 Filed by: Cheng Andrew
3/15
04:46 pm
akro
Form 4 Akero Therapeutics, Inc. For: Mar 13 Filed by: White William Richard
Medium
Report
Form 4 Akero Therapeutics, Inc. For: Mar 13 Filed by: White William Richard
3/15
04:46 pm
akro
Form 4 Akero Therapeutics, Inc. For: Mar 13 Filed by: Young Jonathan
Medium
Report
Form 4 Akero Therapeutics, Inc. For: Mar 13 Filed by: Young Jonathan
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
3/16
Q4/2019 12/31/2019 EPS -0.550 ZacksConsensus -0.580 ActVsEst 0.030 - Beat
-31.4%
1/21
Form 4 Akero Therapeutics, Inc. For: Jan 16 Filed by: Versant Venture Capital VI, L.P.
-17.4%
3/18
Akero Therapeutics (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity.
-14.8%
9/6
Form 8-K Akero Therapeutics, Inc. For: Sep 05
-13.8%
3/6
Form 4 Akero Therapeutics, Inc. For: Mar 04 Filed by: Adelman Robert J
-9.7%
12/31
Form 4 Akero Therapeutics, Inc. For: Dec 27 Filed by: Versant Venture Capital VI, L.P.
-9.5%
1/2
Form 4 Akero Therapeutics, Inc. For: Dec 31 Filed by: Atlas Venture Fund XI, L.P.
-8.7%
3/31
Form 8-K Akero Therapeutics, Inc. For: Mar 31
-7.8%
12/13
Form 4 Akero Therapeutics, Inc. For: Dec 13 Filed by: Rolph Timothy
-7.8%
1/14
Form 4 Akero Therapeutics, Inc. For: Jan 13 Filed by: Adelman Robert J
-6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register